FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362671682> ?p ?o ?g. }

• W4362671682 abstract "Introduction: Bulevirtide is a first-in-class antiviral drug to treat chronic hepatitis B/D. We investigated the drug-drug interaction potential and pharmacokinetics of high-dose subcutaneous bulevirtide (5 mg twice daily) with organic anion transporting polypeptide 1B1 (OATP1B1) and cytochrome P450 (CYP) 3A4. Methods: This was a single-center, open-label, fixed-sequence drug-drug interaction trial in 19 healthy volunteers. Before and at bulevirtide steady state, participants ingested a single 40 mg dose of pravastatin. A midazolam microdose was applied to quantify CYP3A4 activity. Results: At bulevirtide steady state, pravastatin area under the concentration-time curve (AUC 0–∞ ) increased 1.32-fold (90% CI 1.08-1.61). The 5 mg bulevirtide twice-daily treatment resulted in a mean AUC 0-12 of 1210 h*ng/ml (95% CI 1040-1408) and remained essentially unchanged under the influence of pravastatin. CYP3A4 activity did not change to a clinically relevant extent. As expected, total bile acids increased substantially (35-fold) compared to baseline during bulevirtide treatment. All study medication was well tolerated. Discussion: The study demonstrated that high-dose bulevirtide inhibited OATP1B-mediated hepatic uptake of the marker substrate pravastatin but the extent is considered clinically not relevant. Changes in CYP3A4 activity were also not clinically relevant. In conclusion, this study suggests that OATP1B substrate drugs as well as CYP3A4 substrates may safely be used without dose adjustment in patients treated with bulevirtide. However, in patients using high statin doses and where concomitant factors potentially further increase statin exposure, caution may be required when using bulevirtide." @default.
• W4362671682 created "2023-04-07" @default.
• W4362671682 creator A5000865600 @default.
• W4362671682 creator A5006607584 @default.
• W4362671682 creator A5030416479 @default.
• W4362671682 creator A5031890270 @default.
• W4362671682 creator A5040542934 @default.
• W4362671682 creator A5057183308 @default.
• W4362671682 creator A5061579819 @default.
• W4362671682 creator A5075947367 @default.
• W4362671682 creator A5080035541 @default.
• W4362671682 creator A5088331855 @default.
• W4362671682 creator A5090868065 @default.
• W4362671682 date "2023-04-06" @default.
• W4362671682 modified "2023-10-18" @default.
• W4362671682 title "Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers" @default.
• W4362671682 cites W1604547439 @default.
• W4362671682 cites W1783939843 @default.
• W4362671682 cites W1907844212 @default.
• W4362671682 cites W1964471078 @default.
• W4362671682 cites W1966846971 @default.
• W4362671682 cites W1974999149 @default.
• W4362671682 cites W1982950748 @default.
• W4362671682 cites W1990266227 @default.
• W4362671682 cites W2002121467 @default.
• W4362671682 cites W2007238584 @default.
• W4362671682 cites W2008078890 @default.
• W4362671682 cites W2016061838 @default.
• W4362671682 cites W2022663382 @default.
• W4362671682 cites W2023948696 @default.
• W4362671682 cites W2034947261 @default.
• W4362671682 cites W2039470011 @default.
• W4362671682 cites W2039688545 @default.
• W4362671682 cites W2039986849 @default.
• W4362671682 cites W2048397943 @default.
• W4362671682 cites W2049347116 @default.
• W4362671682 cites W2066368473 @default.
• W4362671682 cites W2070128988 @default.
• W4362671682 cites W2071699268 @default.
• W4362671682 cites W2081656085 @default.
• W4362671682 cites W2082749288 @default.
• W4362671682 cites W2087015670 @default.
• W4362671682 cites W2088160623 @default.
• W4362671682 cites W2105734177 @default.
• W4362671682 cites W2107983386 @default.
• W4362671682 cites W2113719939 @default.
• W4362671682 cites W2115151001 @default.
• W4362671682 cites W2117610565 @default.
• W4362671682 cites W2120426460 @default.
• W4362671682 cites W2127191771 @default.
• W4362671682 cites W2158950656 @default.
• W4362671682 cites W2219809513 @default.
• W4362671682 cites W2252904236 @default.
• W4362671682 cites W2396178441 @default.
• W4362671682 cites W2398313845 @default.
• W4362671682 cites W2465490941 @default.
• W4362671682 cites W2569599017 @default.
• W4362671682 cites W2613600150 @default.
• W4362671682 cites W2617224210 @default.
• W4362671682 cites W2770913849 @default.
• W4362671682 cites W2809051650 @default.
• W4362671682 cites W2891216657 @default.
• W4362671682 cites W2938610700 @default.
• W4362671682 cites W2962913477 @default.
• W4362671682 cites W2990181696 @default.
• W4362671682 cites W3092847677 @default.
• W4362671682 cites W3160979354 @default.
• W4362671682 cites W3170469430 @default.
• W4362671682 cites W3176962488 @default.
• W4362671682 cites W339179129 @default.
• W4362671682 cites W4281609246 @default.
• W4362671682 cites W4283384428 @default.
• W4362671682 cites W4283811705 @default.
• W4362671682 cites W4295838443 @default.
• W4362671682 cites W4312210020 @default.
• W4362671682 doi "https://doi.org/10.3389/fphar.2023.1128547" @default.
• W4362671682 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37089922" @default.
• W4362671682 hasPublicationYear "2023" @default.
• W4362671682 type Work @default.
• W4362671682 citedByCount "0" @default.
• W4362671682 crossrefType "journal-article" @default.
• W4362671682 hasAuthorship W4362671682A5000865600 @default.
• W4362671682 hasAuthorship W4362671682A5006607584 @default.
• W4362671682 hasAuthorship W4362671682A5030416479 @default.
• W4362671682 hasAuthorship W4362671682A5031890270 @default.
• W4362671682 hasAuthorship W4362671682A5040542934 @default.
• W4362671682 hasAuthorship W4362671682A5057183308 @default.
• W4362671682 hasAuthorship W4362671682A5061579819 @default.
• W4362671682 hasAuthorship W4362671682A5075947367 @default.
• W4362671682 hasAuthorship W4362671682A5080035541 @default.
• W4362671682 hasAuthorship W4362671682A5088331855 @default.
• W4362671682 hasAuthorship W4362671682A5090868065 @default.
• W4362671682 hasBestOaLocation W43626716821 @default.
• W4362671682 hasConcept C109650736 @default.
• W4362671682 hasConcept C112705442 @default.
• W4362671682 hasConcept C126322002 @default.
• W4362671682 hasConcept C185592680 @default.
• W4362671682 hasConcept C2776839432 @default.
• W4362671682 hasConcept C2778163477 @default.
• W4362671682 hasConcept C2779384505 @default.

• next